Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
IPO Year: 2018
Exchange: NASDAQ
Website: aptorumgroup.com
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K/A - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
S-8 - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
20-F - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
6-K - Aptorum Group Ltd (0001734005) (Filer)
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2022 annual general meeting of shareholders, which was held on December 21, 2022, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all seven directors to hold office until the next annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP (formerly know
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced the results of its 2021 annual general meeting of shareholders, which was held on December 2, 2021, in Hong Kong. At the annual general meeting, the required number of shareholders of the Company: Re-elected all of the Company's current directors, namely Mr. Ian Huen, Mr. Darren Lui, Dr. Clark Cheng, Mr. Charles Bathurst, Dr. Mirko Scherer, Professor Justin Wu and Professor Douglas Arner as directors of the Company until the Company's next annual general meeting o
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing
ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (NASDAQ:APM, PARIS:APM) and ASP Isotopes Inc. (NASDAQ:ASPI) on The RedChip Money Report® on Bloomberg TV, this Saturday, March 18, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aptorum Group Limited (NASDAQ:APM): https://www.aptoruminfo.com/interview_accessASP Isotopes Inc. (NASDAQ:ASPI): https://aspiinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years
ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, November 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO and Executive Chairman Darren Lui discusses the Company's pipeline for oncology, autoimmune, and infectious diseases, a $15 billion market opportunity, the comp
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2022. "During the first half of 2022, we remained focused on advancing the development of our therapeutic programs. As announced in early 2022, both our SACT-1 program (targeting neuroblastoma) and ALS-4 program (targeting MRSA), has announced the completion and positive Phase I clinical trial results. Our RPIDD program (liquid biopsy based approach to infectious
ORLANDO, FL / ACCESSWIRE / September 23, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM)(PARIS:APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, September 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.S. patents, and much more.Ac
NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, on The RedChip Money Report® on Bloomberg TV, this Saturday, August 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Aptorum's CEO Darren Lui discusses the development and commercialization of their novel therapeutics, their diagnostic product, their granted U.
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented "Aptorum's operational plans remain on track. In particular, our lead projects, ALS-4 (targeting infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)) and SACT-1 (targeting neuroblast
Regulatory News: Aptorum Group Limited (NASDAQ:APM, Euronext Paris: APM))) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2021. "During the first half of 2021, we remained focused on advancing the development of our therapeutic programs. As announced in early 2021, our ALS-4 program (targeting infections caused by Staphylococcus aureus including MRSA) commenced a Phase 1 clinical study in Canada. We are pleased that 5 total cohorts, which represent the essential part of the single as
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, "Throughout 2023, we have maintained a strategic focus on the progression of our lead projects to effectively utilize our resources. Additionally, the previously announced proposed reverse merger with YOOV Group Holding demonstrates our commitment to shareholder interests a
Aptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Aptorum's and YOOV's shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing", and the da
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. "During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our ALS-4 and SACT-1 clinical programs and our PathsDx liquid biopsy program through potential collaborations. In light of the macroeconomic environment, we remain vigilant at controlling costs and resources of the company whilst continuing
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office until the third annual meeting of shareholders or until their respective successors are elected and duly qualified; Approved, ratified and confirmed the re-appointment of Marcum Asia CPAs LLP as the Company's independent auditors
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on December 20, 2023). Shareholders of record as of November 10, 2023 are entitled to receive notice of and vote at the annual general meeting. Aptorum filed its annual report on Form 20-F, including its audited financial statements for the fis
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockholder's equity and minimum market value of publicly held shares will be closed. The trading of its Class A ordinary shares will continue on Nasdaq and will not be affected. About Aptorum Group Aptorum Group Limited (NASDAQ:A
Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA. The Phase 1b/2a study of SACT-1 submitted is for the combination with chemotherapy for first relapse or refractory high risk neuroblastoma. Mr. Darren Lui, Chief Executive Officer of Aptorum Group, commented, "Pursuant to an IND opened in September 2021, we have recently submitted a clinical protocol for a P
Regulatory News: Aptorum Group Limited (the "Company") (NASDAQ:APM, PARIS:APM) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the "Aptorum Shares") (ISIN KYG6096M1226) from Euronext Paris. The Board of Euronext has approved this request. Following the delisting from Euronext Paris, the Aptorum Shares will remain listed on the NASDAQ (the "NASDAQ"), the Company's primary listing exchange. Delisting the Aptorum Shares from Euronext Paris has no impact on the NASDAQ listing of Aptorum Shares. A voluntary sales facil
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies to maintain stockholders' equity of at least $10,000,000, and the Company's stockholders' equity was $7,833,305 as
Regulatory News: Aptorum Group Limited (NASDAQ:APM, PARIS:APM) ("Aptorum Group" or "Company"), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited ("ATL") has entered into a non-binding Letter of Intent and Term Sheet ("Term Sheet") to merge ("Transaction") its 100% subsidiary, Paths Innovation Limited and its underlying business (collectively "PathsDx Group") with Universal Sequencing Technology Corporation ("UST"), a San Diego and Boston based US company dedicated to the development and commercialization of advanced proprietary DNA sequencing technologies. Paths Innovation Limited currently holds, through its majority owned subsidiary Paths Diagnostics Pte. Lim
SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13G/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13G - Aptorum Group Ltd (0001734005) (Subject)
SC 13D/A - Aptorum Group Ltd (0001734005) (Subject)
SC 13G - Aptorum Group Ltd (0001734005) (Subject)
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12023334
Re: Amendment to Merger Agreement Dear Wong Ling Yan Philip:Reference is made to that certain Agreement dated March 1, 2024, (the "Merger Agreement") by and between YOOV Group Holding Limited (the "Company") and Aptorum Group Limited (the "ListCo"), relating to a plan of merger and separation. References to capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Merger Agreement.
Gainers Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million. TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago. Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding
Aptorum Gr (NASDAQ:APM) reported quarterly losses of $(0.62) per share. This is a 77.45 percent increase over losses of $(2.75) per share from the same period last year. The company reported $431.38 thousand in sales this quarter. This is a 66.71 percent decrease over sales of $1.30 million the same period last year.
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 67.1% to $5.42 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million. Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 53.88% to $6.54. The company's market cap stands at $111.0 million. As per the press release, Q4 earnings came out 3 days ago. 23andMe Holding (NASDAQ:ME) stock moved upwards by 45.48% to $0.52. The company's market cap stands at $250.2 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 40.75% to $0.05. The company's market cap stands at $6.4 million. iSpecimen (NASDAQ:ISPC) shares moved upwards by 33.19% to $0.28. The company's market cap stands at $
Gainers Dynatronics (NASDAQ:DYNT) stock increased by 70.1% to $0.63 during Monday's after-market session. The company's market cap stands at $3.0 million. Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 14.28% to $1.14. The company's market cap stands at $24.6 million. Aptorum Gr (NASDAQ:APM) shares rose 12.61% to $8.84. The market value of their outstanding shares is at $45.8 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 8.76% to $0.16. The company's market cap stands at $25.9 million. P3 Health Partners (NASDAQ:PIII) shares increased by 8.37% to $0.53. The company's market cap stands at $63.7 million. BioVie (NASDAQ:BIVI) shares rose 7.87% to $0.53. The market value of
Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ETAO International Co., Ltd. (NASDAQ:ETAO) shares shot up 111.5% to $0.3025. The company announced a reverse stock split. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) gained 74.3% to $1.7950 after the company announced plans to acquire The Social Proxy. TruGolf Holdings, Inc. (NASDAQ:TRUG) shares climbed 56% to $1.7938 after the company an
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's market cap stands at $11.0 million. Etao International Co (NASDAQ:ETAO) stock rose 84.65% to $0.26. The company's market cap stands at $26.6 million. Annovis Bio (NYSE:ANVS) shares moved upwards by 39.12% to $12.41. The company's market cap stands at $131.2 million. Brainstorm Cell (NASDAQ:BCLI) stock increased by 33.28% to $0.47. The market value of their outstanding shares is at $23.2 million. SCWorx (NASDAQ:WORX) stock moved upwards by 26.23% to $3.58. The company's market cap stands at $4.3 million. Taysha Gene Therapies (NASDAQ:TSHA) shares increase
Shares of Limbach Holdings, Inc. (NASDAQ:LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Limbach said it sees FY24 revenue of $510 million to $530 million, versus market estimates of $541.1 million. Limbach shares dipped 14.7% to $42.42 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Aptorum Group Limited (NASDAQ:APM) shares climbed 91% to $8.27. Presto Automation Inc. (NASDAQ:PRST) shares jumped 65.2% to $0.3715 after jumping 15% on Wednesday. Cheer Holding, Inc. (NASDAQ:CHR) surged 43.3% to $3.77 following full year 2023 financial results.